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Missing clinical trial data: setting the record straight
Urgent action is needed to restore the integrity of the medical evidence base
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Like us, you have probably grown accustomed to the 
steady stream of revelations about incomplete or sup-
pressed information from clinical trials of drugs and 
medical devices.1 If so, this issue of the BMJ features 
a pair of papers that will dismay but not surprise you. 
Researchers for an official German drug assessment body 
charged with synthesising evidence on the antidepres-
sant reboxetine encountered serious obstacles when 
they tried to get unpublished clinical trial information 
from the drug company that held the data, an experience 
from which they draw several lessons.2 
Once they were able to integrate the astounding 74% 
of patient data that had previously been unpublished, 
their conclusion was damning: reboxetine is “overall an 
ineffective and potentially harmful antidepressant”.3 
This conclusion starkly contradicts the findings of other 
recent systematic reviews and meta-analyses published 
by reputable journals.4-8 These studies presumably met 
prevailing standards for the conduct of meta-analyses. 
Yet we now know that they did not provide a properly 
balanced view of the harms and benefits of reboxetine. 
Why? Because they did not combine all of the existing 
evidence from clinical trials. Furthermore, the difficulties 
encountered by Wieseler and colleagues in obtaining the 
reboxetine data show that routine inquiries about miss-
ing information, which many authors of meta-analyses 
make, are probably insufficient.9 Instead dogged, even 
heroic, persistence is required, as the Cochrane review-
ers trying to untangle the evidence for oseltamivir have 
found.10  11 
Research that is conducted but not reported is only 
part of the problem. Steinbrook and Kassirer point to the 
rosiglitazone (Avandia) story as an example of problems 
arising from incomplete access of researchers and o thers 
to the raw data within a trial.12 Problems also arise, they 
say, with the way in which these data are interpreted 
or adjudicated. They call for journals and editors to do 
more, including reserving the right to inspect trial data 
themselves. This is a contentious topic. Commentator 
Chris Del Mar applauds this stand,13 but Nick Freemantle 
points out that although it is easy to call for unfettered 
access to data, it is another thing entirely to provide and 
make use of it.14
The reboxetine story and similar episodes must call 
into question the entire evidence synthesis enterprise. 
Meta-analyses are generally considered the best form of 
evidence, but is that a plausible world view any longer 
when so many of them are likely to be missing relevant 
information?15 Existing estimates of treatment benefits 
are not always altered when previously unpublished 
clinical trial data become available. At present, how-
ever, we do not know the extent to which integration 
of missing data would support or refute key  portions of 
the existing evidence on which doctors, patients, and 
policy makers rely.
As Wieseler and colleagues point out, the Food and 
Drug Administration Amendments Act of 2007 and par-
allel European efforts will increase the accessibility of 
clinical trial results and make it more difficult to con-
ceal information.2 But they do not solve the problem of 
our current evidence base, which contains incomplete 
and questionable evidence. So what can be done? At 
the moment there are no organised efforts to identify 
missing information and integrate it into the existing 
evidence base.
The BMJ has a particular interest in the impact of 
unpublished data on the overall verdict regarding 
the effectiveness of medical treatment. Because we 
think that it is important to re-evaluate the integrity 
of the existing base of research evidence, the BMJ will 
devote a special theme issue to this topic in late 2011. 
A detailed call for papers will follow, but we mention 
this now because we hope that researchers with such 
projects under way will feel encouraged. We also hope 
that other potential authors might begin now to plan 
suitable projects.
We are especially interested in high quality original 
research that aims to uncover previously unavailable 
data and re-evaluate treatments and practice in light 
of that new evidence. The ideal way to summarise the 
findings would be a formal meta-analysis, showing how 
the newly identified information affects the balance of 
benefit to harm. It is not necessary to conclude that full 
consideration of all of the evidence in fact changes prac-
tice—we will also be interested in papers that conclude 
that, even with new evidence, nothing should change.
Lost in the sometimes rancorous debate over research 
transparency, and the reasons for publication and non-
publication, is the most important thing: efforts are 
needed to restore trust in existing evidence. To that 
end, the BMJ is more interested in constructive use of 
data than finger pointing or blame. We encourage drug 
companies and device manufacturers, as well as aca-
demic researchers, to take advantage of the opportunity 
afforded by our upcoming theme issue. Full information 
about previously conducted clinical trials involving 
drugs, devices, and other treatments is vital to clinical 
decision making. 
It is time to demonstrate a shared commitment to 
 setting the record straight.
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Apgar score and risk of cerebral palsy
Low scores are strongly associated with cerebral palsy and its subtypes
The first large study of Apgar score at birth and the risk 
of cerebral palsy was the US National Collaborative Peri-
natal Project. It found that most cases of cerebral palsy 
occurred in children with normal Apgar scores; that the 
risk of cerebral palsy was strongly related to an Apgar 
score lower than 4 in normal weight infants, especially 
when the low score was prolonged; and that low Apgar 
scores were less predictive of cerebral palsy in low birth-
weight infants.1 
In the linked study, Lie and colleagues confirm—in a 
Norwegian dataset 10 times larger (540 000 children)—all 
of these findings but add the new observation that the 
risk of cerebral palsy by Apgar score depends on the type 
of cerebral palsy. Hemiplegia was 10 times more com-
mon in babies with Apgar score less than 4, diplegia 22 
times more common, but quadriplegia 137 times more 
common.2  
Although the nature of the insult or insults in cerebral 
palsy is still unclear, the Norwegian study suggests that 
for hemiplegia, and perhaps diplegia, the causative expo-
sure might have occurred earlier in gestation than in 
quadriplegia, where the acute effects of the insult might 
still be manifesting at the time of birth. Unfortunately, 
evidence about when a brain damaging event takes place 
in pregnancy is limited, although neuroradiologists are 
making progress in this area.3
Experience suggests that simple procedures that can be 
performed widely have a greater impact on health than 
more complex and demanding procedures that are less 
widely applied. The Apgar scoring system works because 
it comprises just a few components that can easily be 
memorised, and requires no equipment and modest train-
ing.  Each component of the five part scale scores 0, 1, or 
2, providing a score range from 0 to 10. The Apgar score 
is used in delivery rooms around the world, and is even 
recorded on birth certificates in many countries,4 mak-
ing it the only general clinical assessment recorded on 
entire populations, and potentially available for linkage 
to medical records.  
The anaesthesiologist Virginia Apgar created her 
system for scoring a baby’s condition at birth in 1953 
to ensure that doctors and nurses in the delivery room 
would look at the baby.5 She recognised that the intense 
focus on the mother could at times lead to neglect of the 
infant in the crucial first minutes after birth and that if 
systematic assessment of babies at birth was to become 
routine, an assessment tool was needed that was simple 
enough to compete with the hectic environment of the 
delivery room. 
The Apgar score is, as Lie and colleagues highlight, 
a measure of the elusive quality, “vitality.” But where 
does that vitality comes from? The five components of 
the score—colour, heart rate, respiration, reflex irritabil-
ity, and muscle tone—seem to be weighted towards the 
cardiorespiratory system. But a closer look shows that 
the Apgar score is also a neurological examination. Tone 
and reflex irritability are measures of the intactness of 
the nervous system, and respiration, and therefore colour, 
depend on the central drive to breathe.
A low Apgar score, especially when it persists beyond 
the first minute of life, is therefore an indicator of central 
nervous system depression, so it is not surprising that it 
can predict later neurological dysfunction. Although most 
infants with low Apgar scores recover quickly, in a small 
fraction these neurological abnormalities persist and even 
worsen to result in neonatal encephalopathy—a syndrome 
of altered levels of consciousness; abnormal tone; dimin-
ished movement; and, in severe cases, seizures, hypoven-
tilation, and abnormal primitive reflexes.6 All, or nearly 
all, children with low Apgar scores who develop cerebral 
palsy have probably also experienced persistently abnor-
mal neurological findings in the first days of life.7
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The leap from observing signs of neurological depres-
sion at birth to assuming that asphyxia occurred at or 
around birth must be resisted. Objective measures of 
impaired gas exchange around the time of birth correlate 
modestly with a depressed Apgar score at five minutes,8 
and they also correlate poorly with later neurological and 
cognitive outcomes, as Apgar and colleagues were among 
the first to show.9 
What is the lesson for clinical practice? Although com-
plex and expensive technologies are becoming increas-
ingly available, they are no replacement for skills in 
clinical observation. A low Apgar score (<4) at five minutes 
in a baby of normal weight is an important clue that the 
baby has an increased risk of death and disability, even 
though most infants with such scores recover quickly 
and do well. Such babies must be watched closely for the 
persistence or development of encephalopathic signs, 
especially in the light of robust evidence that babies with 
encephalopathy may benefit from head or body cooling.10
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Variation in caesarean delivery rates
Specific risk groups should be monitored at a local level
Rising rates of delivery by caesarean section are a cause of 
concern worldwide. Wide variation has been noted between 
countries—for example, caesarean delivery rates are 15% 
in the Netherlands but 38% in Italy.1 More than twofold dif-
ferences in primary caesarean delivery rates have also been 
reported across regions in Canada,2 and between hospital 
delivery units in the United States and Australia.3  4 Although 
there is no consensus concerning the optimal caesarean 
delivery rate, it is clear that poor access to emergency obstet-
ric care, and hence poor access to caesarean delivery, can 
harm both mother and infant.5 Conversely, high rates of 
operative delivery may result in poorer maternal and infant 
outcomes for the current or subsequent births.6  7 Variations 
in caesarean delivery rates have been attributed to differences 
in the characteristics of women giving birth. In the linked 
study, Bragg and colleagues assess whether the variation in 
unadjusted caesarean section rates between NHS trusts in 
England can be explained by maternal characteristics and 
clinical risk factors.8 
Previous studies have shown that women are more likely to 
be delivered by caesarean section if they are in their first preg-
nancy; older; have previously delivered by caesarean section; 
have a breech presentation; deliver preterm; or have other 
complications of pregnancy or medical problems, including 
diabetes, hypertensive disorders of pregnancy, or obesity.9  10 
However, comparisons of rates of caesarean delivery often 
fail to take these factors into account, with rates not adjusted 
for population differences in these characteristics. Bragg and 
colleagues show significant variation in the rates of caesar-
ean delivery among NHS trusts in England, after adjustment 
for several of these factors.8 Although they were unable to 
investigate some potential explanations—including maternal 
obesity, indication for caesarean section, gestational age at 
delivery, and models of care—persisting differences in these 
factors are unlikely to account for the greater than twofold 
difference in caesarean delivery rates that they calculated—
adjusted rates varied between 15% and 32% among the units 
investigated.
Other suggested reasons for variation in caesarean deliv-
ery rates include contrasting medico-legal environments, 
private compared with public healthcare systems, differ-
ences in delivery volumes, and differences in the training 
of junior obstetricians. These factors are unlikely to explain 
variation between units within the relatively uniform climate 
of NHS hospitals in England. Although maternal choice has 
also been cited as a potential reason for increases in rates 
of caesarean delivery, there is little evidence to suggest that 
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this accounts for much variation in caesarean rates between 
hospitals. Variation is most probably related to differences in 
thresholds for intervention at institutional and practitioner 
levels and variations in the preferred models of care.
This research indicates, at a minimum, the need for more 
informed surveillance of caesarean sections at a hospital, 
regional, and national level. Several approaches could 
achieve this. Perhaps the most straightforward approach 
is the use of the “standard primipara,” whereby units col-
lect specific data on a defined group of low risk women 
only. The “standard primipara” is a 20-34 year old woman, 
who is giving birth for the first time, free of obstetric and 
specific medical complications, and has a singleton term 
pregnancy with a non-small for gestational age infant in a 
cephalic presentation. Comparison of intervention rates in 
this group of women effectively controls for differences in 
population or case mix between units, and it has been used 
to show the impact of guidelines on intrapartum care.11 
An extension of this approach is to divide women into 10 
population subgroups according to specific combinations 
of distinct characteristics: parity, multiple pregnancy, fetal 
presentation, type of labour onset, gestation, and previ-
ous caesarean delivery. This approach allows comparison 
of caesarean delivery rates within comparable population 
subgroups, but it also allows units to establish the contri-
bution to the total caesarean delivery rate made by women 
in each cohort,12 and hence to target approaches to reduce 
the total rate. Both of these approaches require specific 
data collection. Enhancement of routine data to improve 
the monitoring of obstetric care remains an option, but it is 
unlikely that compliance with evidence based practice can 
ever be monitored this way.
It is now 10 years since the national sentinel caesarean 
section audit in the UK, which examined practice in detail,10 
and yet wide variation still exists. Unwarranted variation in 
clinical practice has been cited as an indication of a poor 
quality service.
Bragg and colleagues’ study provides the impetus for 
on going work to investigate and tackle the reasons for regional 
and subregional variations in caesarean  section practice. As 
with the original audit, women and their families, clinicians, 
planners, policy makers, and hospitals would benefit from a 
more detailed examination of variations in caesarean deliv-
ery practice and the generation of the high quality evidence 
needed to inform practice guidelines. High quality popu-
lation based observational studies can provide robust evi-
dence where randomised controlled trials are not possible or 
unethical, and such studies should be encouraged. There is 
no place for poor guidelines based on poor evidence.
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Are measures of patient satisfaction hopelessly flawed? 
No, but they need further refinement
Measures of patient satisfaction and the patient experi-
ence—as instituted in the UK Quality and Outcomes Frame-
work for primary care—supply feedback that helps health 
professionals provide patient centred care; they also give 
insight about the interpersonal dimension of quality of 
care as a complement to the technical quality of care. In 
the linked study, Salisbury and colleagues explore whether 
responses to questions in patient surveys that claim to 
assess the performance of general practices or doctors 
reflect differences between the practices, the doctors, or the 
patients themselves.1 The analysis separates the variance in 
patient satisfaction and patient experience into that attrib-
uted to differences between practices and those between 
doctors. The study found that when patients were asked a 
single question about how satisfied overall they were with 
their practice, only 4.6% of the variance in their satisfac-
tion ratings was a result of differences between practices; 
the remaining variance resulted from differences between 
patients plus random error. In contrast, when asked to 
report on their experience with usual time they had to 
wait for an appointment, more than 20% of the variance 
in responses was a result of differences between practices. 
The authors conclude that for the purpose of discriminating 
performance between practices, it is better to ask patients 
to report on their experience rather than ask for satisfac-
tion ratings. 
Still, the observation that measures of patient satisfaction 
and patient experience vary widely even among patients 
with the same doctor or practice raises questions about their 
use for evaluating practice performance. How can we make 
sense of such variance between patients? Is the use of satis-
faction ratings a hopelessly flawed approach to evaluating 
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practice performance? And what are the implications for 
both measurement and performance evaluation?
Firstly, the variance in satisfaction scores is not surprising 
given the multidimensional nature of health care and patient 
satisfaction. Although satisfaction is seen as a judgment about 
whether expectations were met, it is influenced by varying 
standards, different expectations, the patient’s disposition, 
time since care, and previous experience.2 None the less, qual-
itative research shows that patients will give positive satisfac-
tion ratings even in the face of a negative experience unless 
they believe that the poor care is under the direct control of 
the person they are evaluating.3  4 For example, they may be 
unhappy about hurried communication with their doctor but 
still give an adequate rating because they attribute this to time 
constraints not a lack of intrinsic skills. Consequently, positive 
satisfaction ratings include both true positives and false posi-
tives. This compromises sensitivity in a diagnostic test and by 
the same token reduces the precision of satisfaction ratings. 
In contrast, negative satisfaction ratings tend to be truly nega-
tive (or highly specific in the analogy of diagnostic accuracy) 
and reflect important incidents, such as a lack of respect or 
medical errors.4  5 The implication is that the representation 
of satisfaction and satisfaction ratings needs to be changed. 
It is better to report the proportion of patients who are less 
than totally satisfied rather than the average satisfaction. High 
satisfaction ratings indicate that care is adequate not that it is 
of superior quality; low ratings indicate problems and should 
not be masked by reporting average scores.
Secondly, a defining characteristic of primary care is its 
high degree of variety and variance, even within the practice 
of one doctor.6  7 On a technical note, it is important to remem-
ber that analytical modelling that separates the variance into 
practice, doctor, and patient levels cannot separate variance 
between patients from random error. Part of this random error 
comes from the variation within practices and within doctors, 
which is to be expected, given the complexity of primary care. 
It is not surprising that such complexity can be only partially 
captured by a short questionnaire about experience and satis-
faction. Despite this, patient assessments of health care work 
surprising well. Salisbury and colleagues show that assess-
ments of access explain more variance between practices than 
they do between doctors, which makes sense for an attribute 
related to organisational arrangements. Conversely, assess-
ments of communication explain more variance between doc-
tors than between practices. Other studies have also found 
that patient assessments appropriately detect more variance 
between practices for organisational attributes and between 
doctors for personal care attributes.8  9 The implication is 
that the differences between practices and between doctors 
seen in the current analytical models underestimate the true 
differences that occur at the practice and doctor levels, and 
although Salisbury and colleagues are right in advocating pru-
dence in interpreting small differences between practices, we 
can be confident that statistically significant differences are 
real and clinically relevant.
Thirdly, these results have implications for improving the 
science of measurement. Although it is difficult to measure 
patients’ perceptions of health care, it is most appropriate 
that patients should assess the interpersonal dimension of 
quality of care because they are the ones to whom we are ulti-
mately accountable. It is therefore crucial that patient surveys 
are refined to maximise precision and minimise bias. The 
research community needs to develop and refine robust and 
comparable measures, bearing in mind that deficiencies in 
the measurement of satisfaction are more common in newly 
devised instruments.4
Measures of patient satisfaction need to be refined, but 
they are not hopelessly flawed. When they detect prob-
lems, these are real and important. They should be pre-
sented in a way that highlights the informative negative 
assessments, and they need to be combined with reports 
(such as experience) of components that can be bench-
marked to recognised best practices.
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Misleading communication of risk 
Editors should enforce transparent reporting in abstracts
In 1996 a review of mammography screening reported in 
its abstract a 24% reduction of breast cancer mortality1; 
a review in 2002 claimed a 21% reduction.2 Accordingly, 
health pamphlets, websites, and invitations broadcast 
a 20% (or 25%) benefit.3 Did the public know that this 
impressive number corresponds to a reduction from about 
five to four in every 1000 women, that is, 0.1%? The 
answer is, no. In a representative quota sample in nine 
European countries, 92% of about 5000 women overes-
timated the benefit 10-fold, 100-fold, and more, or they 
did not know.4 For example, 27% of women in the United 
Kingdom believed that out of every 1000 women who were 
screened, 200 fewer would die of breast cancer. But it is 
not only patients who are misled. When asked what the 
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“25% mortality reduction from breast 
cancer” means, 31% of 150 gynae-
cologists answered that for every 1000 
women who were screened, 25 or 250 
fewer would die.3
In 1995, the UK Committee on Safety 
of Medicines issued a warning that 
third generation oral contraceptive 
pills increased the risk of potentially life 
threatening thrombosis twofold. The 
news provoked great anxiety, and many 
women stopped taking the pill, which 
led to unwanted pregnancies and 
abortions––some 13 000 additional 
abortions in the next year in England 
and Wales—and an extra £46m (€55m; 
$71m) in costs for the NHS.5 Yet how 
big was the twofold risk? The studies revealed that for every 
7000 women who took the earlier, second generation pills, 
one had a thrombosis, and this number increased to two 
in women who took third generation pills. The problem of 
misleading reporting has not gone away. In 2009, the BMJ 
published two articles on oral contraceptives and throm-
bosis; one made the absolute numbers transparent in the 
abstract,6 whereas the other reported that “oral contracep-
tives increased the risk of venous thrombosis fivefold.”7
These two examples illustrate a general point. Abso-
lute risks (reductions and increases), such as from one to 
two in 7000, are transparent, while relative risks such as 
“twofold” provide incomplete and misleading risk infor-
mation.3  8 Relative risks do not inform about the baseline 
risk—for example, whether twofold means from one to two 
or from 50 to 100 in 7000—and without this information, 
people overestimate benefits or harms.3  9 In the case of 
the pill scare, the losers were women, particularly ado-
lescent girls, taxpayers, and the drug industry. Reporting 
relative risks without baseline risk is practised not only by 
journalists because big numbers make better headlines or 
by health organisations because they increase screening 
participation rates. The source seems to be medical jour-
nals, from which figures spread to press releases, health 
pamphlets, and the media.
An analysis of the articles published in the Annals of 
Internal Medicine, BMJ, JAMA, Journal of the National Ca ncer 
Institute, Lancet, and the New England Journal of Medicine, 
2003-4, showed that 68% (150/222) failed to report the 
underlying absolute risks in the abstract. Among those, 
about half did report the absolute risks elsewhere in the 
article, but the other half did not.10 Similarly, an analysis 
of 119 systematic reviews in BMJ, JAMA, and Lancet from 
2004 to 2006 showed that every second article discussed 
only relative risks or odds ratios.11
Conveying relative risks without baseline risk is the first 
“sin” against transparent reporting. The second is mis-
matched framing—reporting benefits, such as relative risk 
reductions, in big numbers and harms, such as absolute 
risk increases, in small numbers.3 If we use the example of 
a treatment that reduces the probability of getting disease A 
from 10 to five in 1000, whereas it increases the risk of dis-
ease B from five to 10 in 1000, authors who use mismatched 
framing would report the benefit as a 50% risk reduction and 
the harm as an increase of five in 1000; 
that is, 0.5%. Medical journals permit 
mismatched framing. One in three arti-
cles in the BMJ, JAMA, and Lancet from 
2004 to 2006 used mismatched fram-
ing when both benefits and harms were 
reported.11
Have editors since stopped non-
transparent reporting? To check the 
current situation, we examined the 
abstracts of all free accessible research 
articles published in the BMJ in 2009 
that reported drug interventions. Of 
the 37 articles identified, 16 failed to 
report the underlying absolute num-
bers for the reported relative risk meas-
ures in the abstract. Among these, 14 
reported the absolute risks elsewhere in the article, but two 
did not report them anywhere. Moreover, absolute risks or 
the number needed to treat (NNT) were more often reported 
for harms (10/16) than for benefits (14/27).
How can those who are responsible for accurate commu-
nication of risk do better? And who should be monitoring 
them to ensure that they do? Steps can be taken to improve 
the transparency of risk communication.12 Firstly, editors 
should enforce transparent reporting in journal abstracts: 
no mismatched framing, no relative risks without baseline 
risks, and always give absolute numbers such as absolute 
risks and NNT.
Secondly, institutions that subscribe to medical journals 
could give journal publishers two years to implement the 
first measure and, if publishers do not comply, cancel their 
subscriptions.
Thirdly, writers of guidelines, such as the CONSORT 
statement, should stipulate transparent reporting of ben-
efit and harms in abstracts.
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